Idorsia announces the results of MODIFY, a Phase 3 study of lucerastat in Fabry disease

Application of Jean-Paul and Martine Clozel regarding the exemption from the offer obligation in relation to Idorsia Ltd

Idorsia announces the reference share price and the initial conversion price of convertible bonds successfully placed today

Idorsia successfully completes the offering of convertible bonds, securing funding to develop the company into a leading biopharmaceutical company

Idorsia launches the offering of convertible bonds to fund the development of the company into a leading biopharmaceutical company

Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company

Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction

Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021

European Commission approves Ponvory (ponesimod) for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features

Idorsia holds its Annual General Meeting of Shareholders

Idorsia announces financial results for the first quarter 2021 – substantial progress made across the pipeline – launch preparations well underway

Idorsia issues Notice of the 2021 Annual General Meeting of Shareholders

The European Medicines Agency’s CHMP issues a positive opinion recommending marketing authorisation for Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis

US FDA approves Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis

FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia

Idorsia submits European marketing authorisation application for daridorexant for the treatment of adult patients with insomnia

Idorsia submits NDA for clazosentan to Japanese PMDA

Idorsia announces financial results for 2020 – a successful year marked by outstanding clinical data

Idorsia reports results in relation to the Axovan arbitration – claim dismissed by Arbitral Tribunal

Idorsia to debut at the 39th J.P. Morgan Healthcare Conference – Major catalysts expected in the near-term – Daridorexant NDA submitted to the US FDA